In September 2005, CBPE backed the MBO of Idis, the market leading importer and supplier of unlicensed pharmaceuticals sourced from around the world. Its core activities are: (a) the sourcing and supply (with appropriate regulatory approval) of drugs which are currently unlicensed within a domestic territory from an overseas territory where they are licensed; and (b) the creation of access to drugs still in investigational phase to patients with clear unmet medical needs.

Idis is also the leading provider of global managed access solutions to pharmaceutical and biotech clients. In partnership with these clients, operating on a named-patient basis, Idis provides global services to hospital and retail based pharmacists acting at the request of the prescribing hospital physician.

Idis is based in the US and has its headquarters in the UK.